Loading clinical trials...

Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects

A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of a Single Oral Dose Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects

NCT00498654•Avant Immunotherapeutics

View on ClinicalTrials.gov

Summary

The purpose of this trial is to examine the safety and immunogenicity of Ty800 oral vaccine in healthy adult subjects.

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Healthy Males or Females aged 18 to 55 years, inclusive
•Capable of understanding and complying with the protocol requirements and be available for the duration of the protocol

Exclusion Criteria

•History of malignancy, immunocompromised conditions or currently receiving immunosuppressive treatment including systemic steroids
•History of Typhoid Fever infection, vaccination against typhoid fever or participation in a Clinical Trial using S.typhi organism at any time
•History of travel to a typhoid endemic region within the last 5 years or history of raising a child from an endemic area. Endemic regions are South and East Asia, the Indian Subcontinent, Africa and Central and South America including Mexico
•History of persistent diarrhea, blood in stool, peptic ulcer disease, or inflammatory bowel disease
•Allergies or sensitivities to antibiotics, notably quinolones, penicillins, sulfonamides, cefalosporins and chloramphenicol, and components of the buffer solution, notably aspartame.
•People who are commercial food handlers, day care workers, or health care workers involved in direct patient care. Also people with young children under 2 years of age at home or household contacts who are immunocompromised, pregnant or breast-feeding

Locations (5)

Accelovance LLC

San Diego, California, United States

Accelovance LLC

Melbourne, Florida, United States

Accelovance LLC

Peoria, Illinois, United States

Accelovance LLC

South Bend, Indiana, United States

Accelovance LLC

Houston, Texas, United States

Key Dates

Start Date

July 1, 2007

Primary Completion Date

October 1, 2007

Completion Date

June 1, 2008

Last Updated

July 2, 2008

Enrollment

180

ESTIMATED participants

Conditions

Typhoid Fever

Interventions

Ty800 (Salmonella typhi) Oral Vaccine

BIOLOGICAL

Diagnosis and Staging of Typhoid Fever Using Surface-enhanced Raman Spectroscopy Liquid Biopsy

NCT06546982

Typhoid Fever

View study

COMPLETED

Evaluation Study of DPP® Typhoid Assay

NCT05579821

Typhoid Fever

View study

COMPLETEDPHASE2

Understanding Typhoid Disease After Vaccination

NCT01405521

Typhoid Fever

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 2, 2008Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects

Inclusion Criteria

Exclusion Criteria

Diagnosis and Staging of Typhoid Fever Using Surface-enhanced Raman Spectroscopy Liquid Biopsy

Evaluation Study of DPP® Typhoid Assay

Understanding Typhoid Disease After Vaccination

Vaccines Against Salmonella Typhi

Investigating Enteric Fever - Salmonella Typhi and Paratyphi Challenge Study

Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India